Literature DB >> 24809010

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

Daisuke Okamura1, Akira Matsuda1, Maho Ishikawa1, Tomoya Maeda1, Ken Tanae1, Mika Kohri1, Naoki Takahashi1, Nobutaka Kawai1, Norio Asou1, Masami Bessho1.   

Abstract

Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75 mg/m(2)/daily subcutaneously for 7 days every 28 days. Hematologic improvements were observed according to the International Working Group 2006 criteria after 8 cycles of the azacitidine treatment, and complete remission was achieved after 14 cycles. The grade of myelofibrosis was also improved. The therapeutic activity of azacitidine was confirmed in our MDS-F patient.

Entities:  

Keywords:  Azacitidine; Hematologic improvement; IWG 2006 criteria; MDS; Myelofibrosis

Year:  2014        PMID： 24809010      PMCID： PMC4009407          DOI： 10.1016/j.lrr.2014.03.002

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN： 2213-0489


  12 in total

1.  Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.

Authors:  Katerina E Panteli; Eleftheria C Hatzimichael; Paraskevi K Bouranta; Afroditi Katsaraki; Konstantinos Seferiadis; Justin Stebbing; Konstantinos L Bourantas
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Nicolaus Kröger; Tatjana Zabelina; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Rodrigo Martino; Zi Yi Lim; Francesco Onida; Christoph Schmid; Laurent Garderet; Marie Robin; Michael van Gelder; Reinhard Marks; Argiris Symeonidis; Guido Kobbe; Theo de Witte
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  Decitabine is an effective treatment of idiopathic myelofibrosis.

Authors:  Alexey V Danilov; Valerie Relias; Dianne M Feeney; Kenneth B Miller
Journal:  Br J Haematol       Date:  2008-12-26       Impact factor: 6.998

4.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

5.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors:  Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  Thalidomide in the treatment of myelodysplastic syndrome with fibrosis.

Authors:  Panagiotis Tsirigotis; Evangelos Venetis; Dimitra Rontogianni; John Dervenoulas; Flora Kontopidou; Panos Apostolidis
Journal:  Leuk Res       Date:  2002-10       Impact factor: 3.156

8.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

9.  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  A Quintás-Cardama; W Tong; H Kantarjian; D Thomas; F Ravandi; S Kornblau; T Manshouri; J E Cortes; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

10.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Authors:  Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans M Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544
View more
  2 in total

1.  Prognostic impact of peripheral blood Wilms' tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis.

Authors:  Tomoya Maeda; Akira Matsuda; Chie Asou; Daisuke Okamura; Ken Tanae; Mika Kohri; Maho Ishikawa; Naoki Takahashi; Kunihiro Tsukasaki; Nobutaka Kawai; Norio Asou; Masami Bessho
Journal:  Leuk Res Rep       Date:  2020-12-08

Review 2.  Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.

Authors:  Jing Liang; Fan Yang; Liang Zhao; Chongwei Bi; Benzhi Cai
Journal:  Oncotarget       Date:  2016-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.